EMA Clarifies Clinical Requirements in Adult, Pediatric Heart Failure Trials

Drug Industry Daily
The European Medicines Agency Wednesday released final guidance on the primary and secondary endpoints sponsors should use to evaluate drugs to treat acute heart failure — along with recommendations on designing and conducting such studies in children.

To View This Article:


Subscribe To Drug Industry Daily